Pulse Biosciences (PLSE) Non-Current Debt (2021 - 2023)
Pulse Biosciences (PLSE) posted Non-Current Debt of $65.0 million for Q1 2023, little changed on a QoQ basis from $65.0 million in Q4 2022.
Powered by 
Analysis
Pulse Biosciences (PLSE) Non-Current Debt (2021 - 2023) Analysis & Trends
Pulse Biosciences has reported Non-Current Debt for 3 years, with the latest figure at $65.0 million in Q1 2023.
- On a quarterly basis, Non-Current Debt changed N/A year-over-year to $65.0 million in Q1 2023; TTM through Mar 2023 was $65.0 million, a N/A change from a year earlier, with the FY2022 full-year figure at $65.0 million, changed N/A from the prior year.
- Non-Current Debt was $65.0 million for Q1 2023 at Pulse Biosciences, roughly flat from $65.0 million in the prior quarter.
- The five-year high for Non-Current Debt was $65.0 million in Q3 2022, with the low at $41.0 million in Q1 2021.
- Average Non-Current Debt over 3 years is $59.0 million, with a median of $65.0 million recorded in 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 179.79 Bn | 174.18 Bn | 7.27 Bn | 29.60 Bn |
| 2 | Intuitive Surgical | 127.69 Bn | 122.47 Bn | 1.96 Bn | - |
| 3 | Medtronic | 117.23 Bn | 108.41 Bn | 6.34 Bn | 25.62 Bn |
| 4 | Stryker | 103.55 Bn | 100.07 Bn | 4.50 Bn | 14.19 Bn |
| 5 | Boston Scientific | 63.24 Bn | 62.70 Bn | 3.85 Bn | 10.92 Bn |
| 6 | Edwards Lifesciences | 49.97 Bn | 45.72 Bn | 1.35 Bn | 598.70 Mn |
| 7 | Alcon | 32.83 Bn | 31.37 Bn | 1.68 Bn | -1.00 Mn |
| 8 | Dexcom | 32.30 Bn | 30.35 Bn | 830.00 Mn | - |
| 9 | Steris | 20.73 Bn | 20.25 Bn | 684.20 Mn | 1.65 Bn |
| 10 | Pulse Biosciences | 3.76 Bn | 3.76 Bn | 161,000.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2023 | 65.00 Mn |
| Dec 31, 2022 | 65.00 Mn |
| Sep 30, 2022 | 65.00 Mn |
| Mar 31, 2021 | 41.00 Mn |